Mellar Davis | Pharmacology | Best Researcher Award

Prof. Dr. Mellar Davis | Pharmacology | Best Researcher Award

MD FCCP FAAHPM | Levine Cancer Institute | United States

Dr. Mellar Pilgrim Davis, MD, FCCP, FAAHPM, is a distinguished physician specializing in oncology, hematology, and palliative medicine. With decades of experience in clinical practice, research, and education, he has made significant contributions to supportive cancer care. Dr. Davis has held key academic and clinical positions at renowned institutions, impacting patient care and medical education worldwide.

Profile👤

Scopus

Strengths for the Awards✨

  • Extensive Research and Publications đź“š

    • Dr. Davis has a prolific research career, with significant contributions in oncology, palliative care, and pain management.
    • Recognized as a World Expert in Analgesics (Top 0.1% of scholars per Expertscape).
    • Highly ranked in Symptomatic Treatment (#4) and Palliative Care (#21) by ScholarGPS.
  • Significant Impact in Palliative Medicine 🌿

    • Held leadership roles in the Multinational Association of Supportive Care in Cancer (MASCC), including Chair of the Pain Subgroup.
    • Developed guidelines and educational programs for pain and opioid management in cancer care.
    • Recognized for outstanding contributions to cancer pain management by MD Anderson Cancer Center (2023).
  • Recognized Excellence in Teaching and Mentorship 🎓

    • Multiple Teacher of the Year awards in Cleveland Clinic and Geisinger.
    • Full Professor of Palliative Medicine at Geisinger Commonwealth School of Medicine.
  • Leadership and Professional Influence 🌍

    • Served on NCI, ASCO, ACS, and NCCN panels, shaping research and clinical practice in oncology and palliative care.
    • Co-Chair of the International Conference on Opioids, advancing pain research.

Education🎓

Dr. Davis earned his Bachelor of Science degree from Otterbein College in 1974 and his MD from Ohio State Medical College in 1977. He further honed his expertise through rigorous postdoctoral training, including an Internal Medicine residency at Riverside Methodist Hospital and a Hematology/Oncology fellowship at Mayo Clinic.

Experience👩‍⚕️

Over the years, Dr. Davis has served in various prestigious medical institutions. His career journey includes roles at Toledo Clinic, Milhon Clinic, Columbus Oncology Associates, Cleveland Clinic, and Geisinger Medical Center. Additionally, he has held academic appointments as a Professor of Medicine at Cleveland Clinic Lerner School of Medicine and as a Professor of Palliative Medicine at Geisinger Commonwealth School of Medicine

Research Interests On Pharmacology

đź“ť Dr. Davis’s research focuses on palliative medicine, oncology symptom management, pain control, and ethical issues in cancer care. His work has influenced medical guidelines and practices worldwide, especially in the fields of palliative care and supportive oncology.

Awards and Honors🏆

Dr. Davis has received numerous awards, including the Compassion in Medicine Award, multiple “Best Doctors in America” recognitions, and the Distinguished Service Award from the Multinational Association of Supportive Care in Cancer. He has also been acknowledged as a world expert in analgesics and palliative care.

Publicationsđź“š

  1. Are Muscle and Fat Loss Predictive of Clinical Events in Pancreatic Cancer? The Importance of Precision Metrics

    • Authors: M.P. Davis, N. Bader, J.L. Basting, B. Lagerman, M.J. Wojtowicz
    • Publication Year: 2025
  2. Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits

    • Authors: M.P. Davis
    • Publication Year: 2025
  3. Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study

    • Authors: M.P. Davis, A.M. Ulrich, R. Segal, B.A. Bauer, C.L. Loprinzi
    • Publication Year: 2024
  4. Respiratory Depression Associated with Opioids: A Narrative Review

    • Authors: M.P. Davis, S.L. DiScala, A. Davis
    • Publication Year: 2024
  5. The Surprise Question: Not Ready for Prime Time

    • Authors: M.P. Davis
    • Publication Year: 2024
  6. Correction to: Opioid Analgesic Dose and Route Conversion Ratio Studies: A Scoping Review to Inform an eDelphi Guideline

    • Authors: M.P. Davis, A.N. Davies, M.L. McPherson, E.D. Bruera, C.I. Ripamonti
    • Publication Year: 2024
  7. Understanding The Number Needed to Treat

    • Authors: M.P. Davis, E.A. Vanenkevort
    • Publication Year: 2024
  8. Opioid Analgesic Dose and Route Conversion Ratio Studies: A Scoping Review to Inform an eDelphi Guideline

    • Authors: M.P. Davis, A.N. Davies, M.L. McPherson, E.D. Bruera, C.I. Ripamonti
    • Publication Year: 2024
  9. Fentanyl Pharmacokinetic Paradoxical in Cancer Cachexia

    • Authors: M.P. Davis
    • Publication Year: 2024

Conclusion🎯

Dr. Mellar Pilgrim Davis has dedicated his career to improving cancer care and palliative medicine. Through his extensive research, clinical expertise, and commitment to education, he has left an enduring impact on patient care and medical knowledge. His legacy continues to inspire healthcare professionals worldwide.

Zhiyang Zack Zou | Pharmacology | Best Researcher Award

Dr. Zhiyang Zack Zou | Pharmacology | Best Researcher Award

Drug metabolism and pharmacokinetics | Research Institute | United States

Dr. Zhiyang Zack Zou, Ph.D., is a distinguished scientist with over 30 years of expertise in drug discovery and development. His contributions span across renowned organizations, including Eli Lilly, Lundbeck USA, and the Global Health Drug Discovery Institute (GHDDI). Specializing in CNS, diabetes, oncology, and infectious diseases, Dr. Zou has successfully completed 20+ preclinical IND studies and has extensive experience in DMPK, bioanalysis, and toxicology. His dedication has earned him multiple awards for his innovative contributions to drug development.

Profile

Scopus

Strengths for the Awards

  • Extensive Experience in Drug Discovery and Development
    • Over 30 years of significant contributions in pharmaceutical R&D, spanning CNS, diabetes, oncology, infectious diseases, and more.
    • Led 20+ preclinical IND studies for FDA filing, with expertise in small molecules, biologics, and regulatory standards.
  • Diverse Skill Set
    • Profound knowledge in DMPK (Drug Metabolism and Pharmacokinetics), Toxicology, Bioanalysis, and Pharmacokinetic-Pharmacodynamic (PK/PD) modeling.
    • Expert in applying advanced tools like LC-MS/MS, Phoenix WinNonlin, and PBPK modeling for human dose predictions and drug interaction studies.
  • Leadership and Team Contributions
    • Recognized leader with several awards, such as the “Contribution Award GHDDI 2023” and “Breakthrough Award 2022” for work on Covid-19 3CLPro inhibitors.
    • Proven ability to lead large teams (e.g., managing 60+ team members at Sundia Meditech) and develop high-performance research groups.
  • Global Collaborations and Achievements
    • Worked with world-renowned pharmaceutical companies (e.g., Eli Lilly, Neurocrine Biosciences, Lundbeck).
    • Successfully advanced projects from early discovery to clinical stages, contributing to FDA-approved drugs like Orilissa and Indiplon.
  • Academic Excellence
    • Holds a Ph.D. in Clinical/Bioanalytical Chemistry, with additional advanced education in biochemistry and chemistry.
    • Authored and co-authored numerous impactful publications in high-ranking journals, contributing to both applied and theoretical drug development.
  • Patents and Innovations
    • Holder of patents, such as for pharmaceutical compositions targeting coronavirus infections, showcasing innovation in addressing urgent global health challenges.
  • Training and Certification
    • Well-trained in state-of-the-art pharmacological methodologies, ensuring cutting-edge approaches in research.

Education 🎓

  • Ph.D. in Clinical/Bioanalytical Chemistry – Cleveland State University/Cleveland Clinic Foundation
  • Master’s in Biochemistry – Shanghai Institute of Biochemistry, Chinese Academy of Sciences
  • Bachelor’s in Chemistry – Peking University, Beijing, China

Dr. Zou’s academic journey laid the foundation for his groundbreaking research and industry contributions, particularly in bioanalytical chemistry and biochemistry.

Professional Experience 🏢

Head of DMPK and Toxicology, GHDDI (2019–Present):

  • Led breakthrough projects like COVID-19 3CLPro inhibitors and anti-malaria drugs.
  • Recognized with multiple accolades, including “Breakthrough Award 2022”.

Vice President, Sundia Meditech (2015–2019):

  • Directed a team of 60+ scientists, leading multiple preclinical IND filings.

Associate Director, Eli Lilly (2013–2015):

  • Worked on type-2 diabetes drug discovery, specializing in PK/PD modeling and human dose predictions.

Dr. Zou has also contributed to Lundbeck, Neurogen, and Neurocrine Biosciences, showcasing his leadership and innovative strategies in drug metabolism and bioanalysis.

Research Interests On Pharmacology 🔬

Dr. Zou is passionate about:

  • Drug metabolism, pharmacokinetics (PK/PD), and toxicology
  • ADME studies and human dose projections
  • Developing solutions for diseases like CNS disorders, oncology, and infectious diseases
  • Modeling and simulation for drug development

Awards 🏆

  • GHDDI Contribution Award (2023)
  • Breakthrough Awards (2020 & 2022) for COVID-19 and malaria research
  • Best Team Awards at Sundia Meditech (2016–2018)
  • Numerous accolades for contributions to IND filings and innovative bioanalysis

Publications đź“š

1. Investigation of liquid chromatography–mass spectrometry analysis of a peptide aldehyde SJA6017 with identifying its hemiacetal, gem-diol, and enol ether

  • Authors: Zou, Z.Z., Han, M.-J.
  • Journal: Journal of Mass Spectrometry
  • Year: 2024
  • Citations: 0

2. Enabling a novel solvent method on Albendazole solid dispersion to improve the in vivo bioavailability

  • Authors: Han, M.-J., Zou, Z.Z.
  • Journal: European Journal of Pharmaceutical Sciences
  • Year: 2024
  • Citations: 2

Conclusion ✨

Dr. Zhiyang Zack Zou is a visionary leader in pharmaceutical sciences, with profound expertise in drug discovery and development. His illustrious career, filled with significant achievements, continues to inspire advancements in medical research and therapeutic innovations.